DxPx Conference – the New Meeting Venue for the Diagnostics and Research Tools Industry

International top-level speakers and panelists

DUSSELDORF, Germany – The countdown is on for DxPx Conference, which will start on November 18, 2019 in Dusseldorf, Germany, at Maritim Hotel. The conference program features a range of cutting-edge panel discussions with international top-level participants. DxPx Conference is the world’s first international partnering conference specifically created for the diagnostics and research tool industry. The event targets established companies, start-ups and investors and is organized in tandem with MEDICA to also attract participants from Asia and the US.

Panel topics include cost replacement strategies for new diagnostics and research tool procedures, benefits of multinational partnerships in the creation of new companies, and insights into how point-of-care-diagnostics may eventually replace central laboratories.

Panels will host representatives of venture capital funds, banks, health insurance companies, as well as diagnostics, pharmaceutical and biotech companies. “When we designed a conference dedicated specifically to diagnostics and research tools we were hoping that this would meet with a strong interest in the market. However, we are overwhelmed by the eager participation of so many renowned international speakers and panelists”, says Dr. Mirko Stange, DxPx initiator.

More than 25 top-level speakers have confirmed their participation. Podiums will be headed for example by:

  • Sascha Alilovic, Partner SHS Capital
  • Babette Güldenpfennig, Head of Global Licensing Roche Diagnostics
  • Christoph Hegersberger, VP R&D Thermo Fisher Scientific
  • Daniel Nothelfer, VP Business Development Danaher
  • Dr. Anne Postulka, Senior Director, Medical Economic Value Cepheid
  • Michael Rossbach, Head of Technology Scouting Eppendorf AG

“Attendees do not only have the option to participate in these panels, they can also arrange for 20 minute one-to-one-meetings with potential business partners or investors well before the beginning of the fair. This creates major added value to their MEDICA visit”, explains Dr. Mirko Stange. “For our first DxPx we have already signed on more than 300 registrations from decision makers, investors, and founders in over 20 countries.”

DxPx Conference sponsors are the world’s biggest medical trade fair MEDICA, Roche Diagnostics, Sonic Healthcare’s Bioscientia, business intelligence provider Research Analytica, Pillar Biosciences, Aescuvest, SHS Capital, Plug&Play, NRWBank, EIT Health, McDermott Will & Emery, Brown Gibbons Lang & Company, Medicover and Europe’s leading start-up investor Hightech-Gründerfonds.

Journalists are invited to attend by registering online using the voucher DxPx2019_Press_Partners.

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.